MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
1.330
-0.020
-1.48%
Pre Market: 1.290 -0.04 -3.01% 04:59 05/31 EDT
OPEN
1.400
PREV CLOSE
1.350
HIGH
1.400
LOW
1.270
VOLUME
100
TURNOVER
--
52 WEEK HIGH
31.00
52 WEEK LOW
1.270
MARKET CAP
8.91M
P/E (TTM)
-0.1066
1D
5D
1M
3M
1Y
5Y
Palisade Bio Has Received A Decision To Grant European Patent Number EP3209306 Titled "Stable Neural Stem Cells Comprising An Exogenous Polynucleotide Coding For A Growth Factor And Methods Of Use Thereof"
Benzinga · 6d ago
Palisade Bio's LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
Benzinga · 6d ago
Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NASDAQ · 05/23 13:55
Ladenburg Thalmann Maintains Palisade Bio (PALI) Buy Recommendation
NASDAQ · 05/17 07:18
Ladenburg Thalmann Maintains Buy on Palisade Bio, Lowers Price Target to $16
Benzinga · 05/16 12:23
--Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating
--Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating
MT Newswires · 05/16 08:59
Maxim Group Keeps Their Buy Rating on Palisade Bio (PALI)
TipRanks · 05/13 14:15
Palisade Bio GAAP EPS of -$0.54, revenue of $0.25M
Seeking Alpha · 05/12 13:31
More
About PALI
Palisade Bio, Inc. is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company’s approach is founded on the discovery that damage to the intestinal epithelial barrier can result in the leakage of digestive enzymes from the gastrointestinal (GI) tract into the peritoneal cavity, which can damage tissues and promote inflammation, causing a broad array of acute and chronic conditions. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the well-characterized digestive enzyme inhibitor tranexamic acid (TXA), which is being developed for administration prior to surgeries that are at risk of disrupting the intestinal epithelial barrier. LB1148 is formulated as an aqueous solution for oral (enteral) administration. In addition to TXA, the LB1148 formulation contains polyethylene glycol, carbohydrates, and electrolytes.

Webull offers kinds of Palisade Bio Inc stock information, including NASDAQ:PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.